These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11839513)
1. New promises for schizophrenia therapy. Sridhar N Drug Discov Today; 2002 Feb; 7(4):215-6. PubMed ID: 11839513 [No Abstract] [Full Text] [Related]
2. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. Busatto GF; Pilowsky LS; Ell PJ; Costa DC; Verhoeff NP; Kerwin RW Br J Psychiatry; 1993 Dec; 163():833-4. PubMed ID: 7508329 [No Abstract] [Full Text] [Related]
3. Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties. Heylen SL; Gelders YG Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():180A-181A. PubMed ID: 1379877 [No Abstract] [Full Text] [Related]
4. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia? Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972 [TBL] [Abstract][Full Text] [Related]
5. Prospects for pharmacotherapy of schizophrenia. Pickar D Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875 [No Abstract] [Full Text] [Related]
6. D2 antagonist augmentation in patients with a partial response to atypical antipsychotics. Mazeh D; Melamed Y; Weizman A Can J Psychiatry; 2004 Apr; 49(4):281-2. PubMed ID: 15147030 [No Abstract] [Full Text] [Related]
11. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study. Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945 [TBL] [Abstract][Full Text] [Related]
12. Iloperidone for the management of adults with schizophrenia. Crabtree BL; Montgomery J Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386 [TBL] [Abstract][Full Text] [Related]
13. Schizophrenia: from dopamine to glutamate and back. Carlsson ML; Carlsson A; Nilsson M Curr Med Chem; 2004 Feb; 11(3):267-77. PubMed ID: 14965231 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of risperidone on positive features of schizophrenia. McEvoy JP J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904 [TBL] [Abstract][Full Text] [Related]
15. (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Jin GZ; Zhu ZT; Fu Y Trends Pharmacol Sci; 2002 Jan; 23(1):4-7. PubMed ID: 11804640 [No Abstract] [Full Text] [Related]
16. Dopamine and antipsychotic drug action revisited. Jones HM; Pilowsky LS Br J Psychiatry; 2002 Oct; 181():271-5. PubMed ID: 12356650 [No Abstract] [Full Text] [Related]
17. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia. Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973 [TBL] [Abstract][Full Text] [Related]
18. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Spooren W; Riemer C; Meltzer H Nat Rev Drug Discov; 2005 Dec; 4(12):967-75. PubMed ID: 16341062 [TBL] [Abstract][Full Text] [Related]